Evidence map›Paper›PMID 37893113›Full record

ArticleBiomedicines2023

An Innovative Solution Based on TSCA-ViT for Osteosarcoma Diagnosis in Resource-Limited Settings.

Zengxiao He, Jun Liu, Fangfang Gou, Jia Wu

Abstract read
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zengxiao HeSchool of Computer Science and Engineering, Central South University, Changsha 410083, China.
Jun LiuThe Second People's Hospital of Huaihua, Huaihua 418000, China.
Fangfang GouState Key Laboratory of Public Big Data, College of Computer Science and Technology, Guizhou University, Guiyang 550025, China.
Jia WuSchool of Computer Science and Engineering, Central South University, Changsha 410083, China.ORCID 0000-0001-9013-0818

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identifying and managing osteosarcoma pose significant challenges, especially in resource-constrained developing nations. Advanced diagnostic methods involve isolating the nucleus from cancer cells for comprehensive analysis. However, two main challenges persist: mitigating image noise during the capture and transmission of cellular sections, and providing an efficient, accurate, and cost-effective solution for cell nucleus segmentation. To tackle these issues, we introduce the Twin-Self and Cross-Attention Vision Transformer (TSCA-ViT). This pioneering AI-based system employs a directed filtering algorithm for noise reduction and features an innovative transformer architecture with a twin attention mechanism for effective segmentation. The model also incorporates cross-attention-enabled skip connections to augment spatial information. We evaluated our method on a dataset of 1000 osteosarcoma pathology slide images from the Second People's Hospital of Huaihua, achieving a remarkable average precision of 97.7%. This performance surpasses traditional methodologies. Furthermore, TSCA-ViT offers enhanced computational efficiency owing to its fewer parameters, which results in reduced time and equipment costs. These findings underscore the superior efficacy and efficiency of TSCA-ViT, offering a promising approach for addressing the ongoing challenges in osteosarcoma diagnosis and treatment, particularly in settings with limited resources.

Indexed as

cell nucleus segmentationcomputational efficiencyimage noise reductionmachine learningosteosarcomapathology slide imagesresource-limited settingstwin-self and cross-attention vision transformer (TSCA-ViT)

Identifiers

PMID37893113
PMCPMC10604772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.